李绍燕

【摘 要】：目的：观察分析四逆散合二陈平胃散加减治疗痰湿阻滞型幽门螺杆菌阳性相关慢性胃炎的临床效果。方法：选取2018年7月至2019年7月本院收治的84例痰湿阻滞型幽门螺杆菌阳性慢性胃炎患者，采用随机分组形式對其分为对照组和研究组，每组各42例，对照组使用抗幽门螺杆菌四联治疗法，研究组使用四逆散合二陈平胃散加减予以治疗。结果：研究组患者临床治疗总有效率（97.62%）显著高于对照组患者临床治疗总有效率（80.95%）;研究组患者胃镜治疗总有效率（100.00%）显然高于对照组胃镜治疗总有效率（83.33%）。结论：四逆散合二陈平胃散加减治疗痰湿阻滞型幽门螺杆菌阳性相关慢性胃炎的临床效果显著，有效减少患者症状时间，改善患者病症，降低患者幽门螺旋杆菌感染率，值得临床推广应用。

【关键词】：四逆散合;二陈平胃散加减;幽门螺杆菌阳性;慢性胃炎

Abstract： objective： to observe and analyze the clinical effect of si ni SAN and er Chen ping wei SAN in the treatment of chronic gastritis associated with positive helicobacter pylori of phlegm-dampness-blocking type. Selection methods： July 2018 to July 2019 in our hospital treated 84 cases of phlegm wet block type positive helicobacter pylori patients with chronic gastritis， adopt random grouping form for its divided into control group and research group， 42 cases in each group and the control group using four league against helicobacter pylori therapy， the team used four inverse scattering in two Chen ping treatment stomach powder. Results： the total effective rate of the study group （97.62%） was significantly higher than that of the control group （80.95%）. The total effective rate （100.00%） in the study group was significantly higher than that in the control group （83.33%）. Conclusion： siyinsan combined with erchenpingwei powder has a significant clinical effect in the treatment of chronic gastritis associated with positive helicobacter pylori of phlegm-dampness-blocking type， effectively reducing the duration of symptoms， improving symptoms， and reducing the infection rate of helicobacter pylori in patients， which is worthy of clinical promotion and application.

Key words： si inverse sanhe; Chenping stomach powder plus or minus; Positive for helicobacter pylori; Chronic gastritis

幽门螺杆菌属于常见性慢性胃炎症状，其主要发病原因是患者肝郁脾虚，痰湿阻滞证。针对这类病症应以健脾疏肝、祛湿化痰以主，以此修复患者胃黏膜损伤。本文将对四逆散合二陈平胃散加减治疗痰湿阻滞型幽门螺杆菌阳性相关慢性胃炎的临床效果予以观察分析，其报道如下。

1 资料与方法

1.1 一般资料

对照组42例，使用抗幽门螺杆菌四联治疗法，男性22例，女性20例，年龄21～69岁，平均年龄（43.17±10.28）岁，平均病程（3.91±6.42）;研究组42例，使用四逆散合二陈平胃散加减予以治疗，男性22例，女性20例，年龄23～65岁，平均年龄（42.29±10.97）岁，平均病程（4.12±7.24）年。……